Rimegepant, the only orally disintegrating anti-CGRP tablet, marketed as Nurtec ODT, will be available in a 75-mg dose.
Eptinezumab, Lundbeck’s intravenous monoclonal antibody that will be marketed as Vyepti, will become available for prescription in April 2020 with a recommended dose of 100 mg quarterly.
Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.
Your patient asks if a ketogenic diet can reduce her migraines. What will you tell her?
For years, study participants had been suffering with migraine symptoms and had failed at least three to five therapies before enrolling in the trial.
Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
Take this brief quiz to test your knowledge of recent recommendations from the American Headache Society for the prevention and acute management of migraine.
Is there a connection between this patient’s ocular symptoms and migraines?
This young woman is otherwise healthy and doesn’t drink or abuse drugs. What’s in your differential diagnosis?
The patient has a history of migraine. Is this another attack—or is something else going on?